20.500.12556/DiRROS-19290 Sorafenib for the treatment of hepatocellular carcinoma a single-centre real-world study Background Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was demonstrated in patients with well-preserved liver function and good functional status. In the real-world setting, treatment is often offered to patients outside these criteria. We therefore performed a single-centre real-world cohort study on the efficacy of sorafenib in patients with hepatocellular carcinoma. Patients and methods We identified all patients with hepatocellular carcinoma initiating treatment with sorafenib between January 2015 and January 2018. The primary endpoint was overall survival (OS) since starting sorafenib. Clinical and demographic variables associated with survival were studied. Results The median OS was 13.4 months (95% CI 8.2%18.6). Multivariable Cox%s regression identified worse ECOG performance status (HR 2.21; 95% CI 1.56%3.16; P < 0.0001), Child-Pugh class C (HR 52.4; 95% CI 3.20%859; P = 0.005) and absence of prior locoregional treatment (HR 2.30; 95% CI 1.37%3.86; P = 0.002) to be associated with increased mortality. Conclusions Careful selection of patients for treatment with sorafenib is of paramount importance to optimize outcomes. hepatocellular carcinoma survival sorafenib hepatocelularni karcinom preživetje sorafenib true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-07-12 12:37:04 2024-07-12 12:37:04 2024-07-13 03:49:24 0000-00-00 00:00:00 2020 0 0 Soavtorji: Tajda Kosir Bozic, Borut Stabuc, Rado Jansa; str. 233-236, XI no. 2 Vol. 54 Jun. 2020 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2020-06-01 616-006 1318-2099 10.2478/raon-2020-0027 19073283 https://content.sciendo.com/view/journals/raon/54/2/article-p233.xml 1 b053148c-403a-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26598 RAZ_Hanzel_Jurij_2020.pdf RAZ_Hanzel_Jurij_2020.pdf 1 5D63BCBB6C7886967726D16ED3234BF1 0b05b01dff02e47676cf6e430ba16fc1660e076260c03b4ae8416031ffecb4dd daf58b3a-403a-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26599 Onkološki inštitut Ljubljana 0 0 0